Positron emission tomography/computed tomography for optimized colon cancer staging and follow up

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 191-201

  Engelmann, Bodil Elisabeth ^a,b   Loft, Annika ^b   Kjær, Andreas ^b,c   Nielsen, Hans Jorgen ^d   Berthelsen, Anne Kiil ^b   Binderup, Tina ^b,c   Brinch, Kim ^a   Brünner, Nils ^c   Gerds, Thomas Alexander ^e   Hoyer Hansen, Gunilla ^e,f,h   Kristensen, Michael Holmsgaard ^a   Kurt, Engin Yeter ^b   Latocha, Jan Erik ^g   Lindblom, Gunnar ^b   Sloth, Carsten ^a   Hojgaard, Liselotte ^b  

^a NAESTVED HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f FINSEN LABORATORY   (Denmark)

^g SLAGELSE HOSPITAL   (Denmark)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carcinoembryonic antigen; Colonic neoplasms; Colorectal neoplasms; Neoplasm staging; Positron emission tomography; Prognosis; Receptors; Tissue inhibitor of metalloproteinase 1; Urokinase plasminogen activator; X ray computed tomography

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; IOVERSOL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLON TUMOR; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PET-CT SCANNER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CARCINOMA; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; COLONIC NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84892706965     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.863967     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. 2008. Int J Cancer 2010;127:2893-917.
2. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 2010;28: 256-63.
3. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-71.
4. Dewhurst C, Rosen MP, Blake MA, Baker ME, Cash BD, Fidler JL, et al. ACR Appropriateness Criteria pretreatment staging of colorectal cancer. J Am Coll Radiol 2012;9: 775-81.
5. Scholefield JH MC, Maughan TS, Shepherd NA, Steele RJC, Thompson MR, Cunliffe WJ, et al. Guidelines for the management of colorectal cancer. London, UK: The Association of Coloproctology of Great Britain and Ireland; 2007.
6. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18) F-FDG PET: a randomized study. J Nucl Med 2009;50: 1036-41.
7. Briggs RH, Chowdhury FU, Lodge JP, Scarsbrook AF. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol 2011;66: 1167-74.
8. Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in preoperative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 2011;15: 1-192; iii-iv.
9. Cipe G, Ergul N, Hasbahceci M, Firat D, Bozkurt S, Memmi N, et al. Routine Use of Positron-emission Tomography/ Computed Tomography for Staging of Primary Colorectal Cancer: Does It Affect Clinical Management? World J Surg Oncol 2013;11:49.
10. Kwak JY, Kim JS, Kim HJ, Ha HK, Yu CS, Kim JC. Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer. World J Surg 2012;36: 1898-905.
11. Mainenti PP, Iodice D, Segreto S, Storto G, Magliulo M, De Palma GD, et al. Colorectal Cancer and 18FDG-PET/ CT: What about Adding the T to the N Parameter in Locoregional Staging? World J Gastroenterol 2011;17:1427-33.
12. Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol 2008;38:347-53.
13. Chan K, Welch S, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in colorectal cancer. Clin Oncol (R Coll Radiol) 2012;24:232-49.
14. Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512-19.
15. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003;3:26.
16. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27:872-7.
17. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007:CD002200.
18. Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008;98:875-80.
19. Sorensen NF, Jensen AB, Wille-Jorgensen P, Friberg L, Rordam L, Ingeman L, et al. Strict follow-up programme including CT and (1)(8)F-FDG-PET after curative surgery for colorectal cancer. Colorectal Dis 2010;e224-8.
20. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
21. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
22. Moller Sorensen N, Vejgaard Sorensen I, Ornbjerg Wurtz S, Schrohl AS, Dowell B, Davis G, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008; 43:774-86.
23. Liu H, Chen B, Lilly B. Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis 2008;11:223-34.
24. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002;8:156-64.
25. Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006;42:1889-96.
26. Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Dano K, et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009;124:1860-70.
27. Lomholt AF, Christensen IJ, Hoyer-Hansen G, Nielsen HJ. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 2010;49:805-11.
28. Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen HJ, Christensen IJ, et al. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem 2010;56:1636-40.
29. Danish Colorectal Cancer Group. National guidelines for diagnostic and treatment of colorectal cancer. 2013. 06. 01. 2013. Available from http://www. dccg. dk/.
30. ImPACT-Scanner-Evaluation-Group. CTDosimetry v1. 0. 4. 2011. Available from http://www. impactscan. org/.
31. Holten-AndersenMN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-HansenG, et al. Quantitation ofTIMP-1 in plasma of healthy blood donors and patients with advanced cancer Br J Cancer 1999;80:495-503.
32. Fleiss J, Cohen J, Everitt B. Large sample standard errors of kappa and weighted kappa. Psychol Bull 1969;72:323-7.
33. R-Core-Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. Available from http://www. r-project. org/.
34. Luboldt W, Volker T, Wiedemann B, Zophel K, Wehrmann U, Koch A, et al. Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off. Eur Radiol 2010; 20:2274-85.
35. Restivo A, Zorcolo L, Piga S, Cocco IM, Casula G. Routine preoperative chest computed tomography does not influence therapeutic strategy in patients with colorectal cancer. Colorectal Dis 2012;14:e216-21.
36. Parnaby CN, Bailey W, Balasingam A, Beckert L, Eglinton T, Fife J, et al. Pulmonary staging in colorectal cancer: a review. Colorectal Dis 2012;14:660-70.
37. Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J, et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. Jama 2006; 296:2590-600.
38. Leufkens AM, van den Bosch MA, van Leeuwen MS, Siersema PD. Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol 2011;46:887-94.
39. Arredondo J, Pastor C, Baixauli J, Rodriguez J, Gonzalez I, Vigil C, et al. Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer. Colorectal Dis 2013;15: 552-7.
40. Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13:1152-60.
41. Huh JW, Jeong YY, Kim HR, Kim YJ. Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer. Ann Oncol 2012;23:1198-206.
42. Danish Colorectal Cancer Group. Danish Colorectal Cancer Group Annual Report 2011 [cited 2013 06. 01. 2013]. Available from http://www. dccg. dk/03-Publikation/02-arsraport- pdf/aarsrapport-2011. pdf.